CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.03
8.42%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.04
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026262 %
Charges from full value of position ($-4.99)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00404 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00404%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.95
Open 1.01
1-Year Change -62.45%
Day's Range 0.99 - 1.11
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 12, 2024 1.03 0.02 1.98% 1.01 1.11 0.99
Jul 11, 2024 0.95 0.03 3.26% 0.92 1.02 0.92
Jul 10, 2024 0.88 0.06 7.32% 0.82 0.93 0.82
Jul 9, 2024 0.82 0.01 1.23% 0.81 0.83 0.76
Jul 8, 2024 0.79 0.09 12.86% 0.70 0.82 0.69
Jul 5, 2024 0.69 -0.01 -1.43% 0.70 0.71 0.66
Jul 3, 2024 0.67 -0.05 -6.94% 0.72 0.72 0.66
Jul 2, 2024 0.72 -0.03 -4.00% 0.75 0.77 0.71
Jul 1, 2024 0.74 -0.14 -15.91% 0.88 0.89 0.74
Jun 28, 2024 0.88 -0.11 -11.11% 0.99 1.03 0.87
Jun 27, 2024 1.00 -0.04 -3.85% 1.04 1.04 0.99
Jun 26, 2024 1.03 -0.12 -10.43% 1.15 1.15 1.02
Jun 25, 2024 1.16 -0.01 -0.85% 1.17 1.17 1.13
Jun 24, 2024 1.17 0.06 5.41% 1.11 1.18 1.10
Jun 21, 2024 1.10 0.05 4.76% 1.05 1.16 1.05
Jun 20, 2024 1.07 0.05 4.90% 1.02 1.11 0.99
Jun 18, 2024 1.01 -0.04 -3.81% 1.05 1.05 1.01
Jun 17, 2024 1.04 -0.07 -6.31% 1.11 1.11 1.04
Jun 14, 2024 1.10 -0.05 -4.35% 1.15 1.15 1.08
Jun 13, 2024 1.14 0.00 0.00% 1.14 1.16 1.09

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

FibroGen, Inc Company profile

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.

Industry: Biotechnology & Medical Research (NEC)

409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US

People also watch

XRP/USD

0.54 Price
-1.340% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,411.42 Price
-0.180% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.60

US100

20,336.40 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

60,039.40 Price
+2.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading